Cystic fibrosis may cause a range of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated liver disease. The committee created updated recommendations and guidance for screening, monitoring, and treating CF-associated hepatobiliary involvement and advanced liver disease, including seven recommendations for screening, 13 for monitoring of existing disease, and 14 for treatment of CF-associated hepatobiliary involvement or advanced liver disease.
Sellers ZM, Assis DN, Paranjabe SM, et al. Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations. Hepatology. 2023 Oct 26. doi:10.1097/HEP.0000000000000646. Online ahead of print.